Multiple MyelomaClinical Notes for Practicing Oncologists
From SLiM-CRAB diagnosis and R2-ISS risk stratification through Dara-VRd/Dara-VTd induction, ASCT workflow, maintenance, and R/R sequencing — including bispecific antibodies and CAR-T.
PERSEUS 4-yr PFS
84.3%
Dara-VRd → ASCT
CASSIOPEIA sCR
39%
Dara-VTd induction
S0777 OS
75 mo
VRd vs Rd
R2-ISS Groups
I–IV
JCO 2022 update
How do you classify, diagnose, and risk-stratify a patient with Multiple Myeloma — from immunochemical subtype to R2-ISS staging?
For the oral boards, "Type of MM" refers to the Immunochemical Classification (what protein is secreted) as well as the Molecular Classification (underlying genetics), which increasingly dictates therapy (e.g., Venetoclax for t(11;14)).
IgG Myeloma
~50–60%
Most common subtype
IgA Myeloma
~20%
Second most common
Light Chain Only
~20%
SPEP often negative
Rare Subtypes
IgD / IgE / IgM-MM
<1–2% each
| Subtype | Frequency | Key Characteristics | Monitoring Pitfall |
|---|---|---|---|
| IgG Myeloma | ~50–60% | Classic CRAB presentation. M-spike distinct in the Gamma region. Hyperviscosity rare unless M-spike >5–6 g/dL. | IgG half-life ~21–23 days — M-protein lags behind true tumour response. |
| IgA Myeloma | ~20% | M-spike often hides in the Beta region (masking with Transferrin/C3). Higher hyperviscosity risk (IgA can polymerize to dimers/trimers). Slightly higher extramedullary disease (EMD). Historically slightly worse than IgG, gap closing with novel agents. | Beta-migration: quantification on SPEP unreliable — rely on IgA nephelometry. |
| Light Chain Only (Bence Jones Myeloma) | ~20% | Clone secretes only κ or λ with no heavy chain. Very high renal failure risk (light chain cast nephropathy). | SPEP often negative or shows hypogammaglobulinemia — light chains filtered by kidneys. Must use sFLC and UPEP. |
| IgD Myeloma | ~1–2% | "Small Spike, Big Disease." >90% Lambda light chain restricted. Younger patients (median age ~50–55). High renal failure, extramedullary disease, advanced ISS stage at diagnosis. | SPEP shows tiny or barely visible M-spike → easily misdiagnosed as Non-Secretory or Light Chain MM. Must specifically quantify IgD. |
| IgE Myeloma | <0.1% | Rarest subtype. Highly associated with t(11;14) (~80–100% of cases). High incidence of extramedullary disease and secondary Plasma Cell Leukemia (sPCL). | SPEP shows small or deceptive M-spike. Often misdiagnosed as Light Chain Only unless IgE-specific antisera used in immunofixation. |
| IgM Myeloma (IgM-MM) | <1% | Must distinguish from Waldenström Macroglobulinemia (WM). IgM-MM has lytic lesions and t(11;14); WM has lymphadenopathy/splenomegaly and MYD88 mutation. | IgM-MM treated as MM (D-VRd + ASCT), not as lymphoma. Venetoclax highly relevant given near-universal t(11;14). |
| Non-Secretory MM | ~1–2% | No detectable M-protein on SPEP, SIFE, or sFLC. Diagnosis relies entirely on bone marrow biopsy and PET/CT to prove end-organ damage. | Cannot use blood markers for monitoring — requires serial PET/CT or marrow exams. |
IgG Key Feature: Placental Crossing
Molecular classification by FISH determines prognosis and future treatment selection, particularly for maintenance strategy and emerging targeted therapy.
Hyperdiploid MM (~45% of patients)
- Genetics: Trisomies of odd-numbered chromosomes (3, 5, 7, 9, 11, 15, 19, 21).
- Prognosis: Generally Standard Risk / Better prognosis.
- Mechanism: Driven by copy number changes, not translocations.
- Standard Risk Trisomies: Favorable or neutral findings by FISH.
Non-Hyperdiploid MM (~40% of patients)
- Genetics: Primary translocations involving the IgH locus on chromosome 14.
- t(11;14): Standard risk. Uniquely targetable by Venetoclax (BCL-2 inhibitor).
- t(4;14): High Risk — associated with FGFR3 upregulation.
- t(14;16): High Risk — associated with c-MAF upregulation.
| Translocation | Risk Category | Key Feature / Therapeutic Implication |
|---|---|---|
| t(11;14) | Standard Risk | Involves CCND1 gene. Targetable by Venetoclax (BCL-2 inhibitor). Present in ~83–100% of IgM-MM and ~80–100% of IgE-MM cases. Historically neutral risk; highly relevant for BCL-2-directed therapy. |
| t(4;14) | High Risk | Associated with FGFR3 upregulation. One of the "Big 4" high-risk FISH abnormalities. |
| t(14;16) | High Risk | Associated with c-MAF upregulation. One of the "Big 4" high-risk FISH abnormalities. |
| Hyperdiploidy (odd trisomies) | Standard Risk | Trisomies 3, 5, 7, 9, 11, 15, 19, 21. Best prognosis group. Driven by copy number changes. |
| t(6;14) | Standard Risk | Rare. Standard risk. |
Venetoclax & t(11;14) — The Targetable Translocation
The workup for suspected MM is designed to confirm the monoclonal protein, quantify bone marrow involvement, and assess for end-organ damage (CRAB/SLiM-CRAB criteria). Standard screening must include all three of the following to achieve >99% sensitivity.
Phase 1: Screening Triplet
- SPEP + IFE (Immunofixation): Identifies M-spike and heavy/light chain isotype.
- Serum Free Light Chain (sFLC) Assay: Essential for light chain myeloma; calculates involved/uninvolved ratio.
- 24-hour Urine UPEP + UIFE: Detects Bence Jones protein, quantifies renal protein loss.
- This triplet achieves >99% sensitivity for detecting MM.
Phase 2: Bone Marrow Evaluation
- Aspirate + Trephine Biopsy: Quantifies plasma cell percentage (diagnostic threshold ≥10%).
- Flow Cytometry: Identifies aberrant phenotypes (CD138+, CD56+, CD19−).
- FISH — Mandatory: Must test for del(17p), t(4;14), t(14;16), t(11;14), 1q21 gain/amp, del(1p).
Phase 3: Imaging (New Standard)
- Whole-Body Low-Dose CT (WBLDCT): Primary screening tool for lytic lesions — NCCN/ESMO preferred. Replaced skeletal survey.
- Whole-Body MRI: Most sensitive for marrow infiltration before bone destruction. Required if WBLDCT negative but SMM suspected.
- PET/CT: Best for identifying extramedullary disease and monitoring treatment response/MRD.
- A negative skeletal survey is no longer sufficient to rule out bone disease.
Phase 4: Laboratory Assessment (CRAB / Staging)
- CBC with differential: Assess for anaemia, thrombocytopenia; peripheral smear for Rouleaux.
- CMP (Comprehensive Metabolic Panel): Creatinine (renal failure), Calcium (hypercalcaemia), Albumin (staging).
- LDH: Required for R-ISS/R2-ISS staging.
- Beta-2 Microglobulin (B2M): Required for ISS and R-ISS/R2-ISS staging.
- Quantitative Immunoglobulins: IgG, IgA, IgM, IgD, IgE.
- Peripheral Blood Smear: Look for Rouleaux formation (stacked coin pattern).
One-Line Workup Summary
Diagnosis requires ≥10% clonal bone marrow plasma cells (or biopsy-proven bony/extramedullary plasmacytoma) PLUS any one Myeloma Defining Event (MDE) from the SLiM-CRAB list below.
SLiM — Biomarkers of Malignancy
Any one of these defines active myeloma even without symptoms:
- S — Sixty %: Clonal bone marrow plasma cells ≥60%.
- Li — Light Chains: Involved/Uninvolved sFLC ratio ≥100 (with the involved light chain ≥100 mg/L).
- M — MRI: >1 focal lesion on MRI that is ≥5mm in size.
CRAB — End-Organ Damage
- C — Calcium: Serum calcium >11 mg/dL (>2.75 mmol/L) OR >1 mg/dL above the upper limit of normal.
- R — Renal: CrCl <40 mL/min OR Serum creatinine >2 mg/dL (>177 µmol/L). Must be attributable to myeloma (cast nephropathy).
- A — Anaemia: Hb <10 g/dL OR >2 g/dL below the patient's baseline.
- B — Bone: One or more osteolytic lesions on CT, PET-CT, or MRI.
The 'Any Level' M-Protein Rule
If a patient has 15% plasma cells and an M-spike of only 0.5 g/dL, but they have a new lytic bone lesion (CRAB-B), they have Active Multiple Myeloma. The presence of end-organ damage trumps the absolute level of the M-protein.| Diagnosis | Serum M-Protein | Bone Marrow Plasma Cells | CRAB Features | SLiM Biomarkers |
|---|---|---|---|---|
| MGUS | <3.0 g/dL | <10% | Absent | Absent |
| Smoldering MM (SMM) | ≥3.0 g/dL | 10–60% | Absent | Absent |
| Active MM | Any level | ≥10% (or plasmacytoma) | Present | Present |
Measurable Disease for Clinical Trials
- Serum M-protein ≥1.0 g/dL
- Urine M-protein ≥200 mg/24 hours
- Involved sFLC ≥10 mg/dL (if the ratio is abnormal)
The 20-2-20 Rule is the gold standard for risk-stratifying Smoldering Multiple Myeloma (SMM), developed by the Mayo Clinic to identify "high-risk" patients with a ~50% risk of progressing to active MM within 2 years.
20 — Plasma Cells
>20%
Bone marrow plasma cells
2 — M-Protein
>2 g/dL
Serum M-protein level
20 — FLC Ratio
>20
Involved/Uninvolved sFLC ratio
Classification: High-Risk SMM requires ≥2 of 3 criteria
| Risk Group (20-2-20) | Factors Met | 2-Year Progression Risk | Management Strategy | Monitoring Frequency |
|---|---|---|---|---|
| Low Risk | 0 factors | ~10% | Observation | Every 6 months |
| Intermediate Risk | 1 factor | ~25% | Observation | Every 3–4 months |
| High Risk | ≥2 factors | ~50% | Clinical Trial or Lenalidomide monotherapy | Every 2–3 months |
The Strategic Debate: "Watch or Treat?"
The standard of care outside of a clinical trial is still observation or Lenalidomide monotherapy:
- The Evidence for Treatment (ECOG E3A06 trial): Lenalidomide significantly delayed progression to active MM vs. observation in high-risk SMM patients.
- The Argument for Observation: No definitive proof yet that early treatment improves Overall Survival (OS). Some experts argue that treating early may "prime" the disease to become more resistant when it eventually relapses.
- Current Recommendation: Discuss risks and benefits with the patient. If highly motivated to delay onset of CRAB symptoms, offer Lenalidomide or enrolment in a clinical trial (e.g., DETERMINATION or ASCENT trials, testing triplets/quadruplets in SMM).
- Standard D-VRd induction is NOT yet standard of care for SMM — even if high-risk criteria are met.
Mock Exam Scenario: Imaging in High-Risk SMM
Examiner: "A patient has ≥25% plasma cells, an M-spike of 1.5 g/dL, and a FLC ratio of 25. What is their risk category, and what imaging would you order?"
Candidate: "This patient meets two of the 20-2-20 criteria (Marrow >20% and FLC ratio >20), placing them in the High-Risk Smoldering category. I would order a Whole-Body MRI or PET/CT. In high-risk smoldering patients, we often find 'silent' bone lesions missed on a standard skeletal survey. If the MRI shows >1 focal lesion, the diagnosis changes from 'Smoldering' to Active MM (based on the 'M' in SLiM), and I would start full induction therapy immediately."
Risk stratification in 2026 has moved beyond simple staging to a dynamic, cytogenetic-driven model. The most critical update to cite is the Second Revision of the International Staging System (R2-ISS), which formally incorporates 1q gain as a high-risk feature — a major omission in the original R-ISS.
ISS Staging — The Foundation
| ISS Stage | Criteria |
|---|---|
| Stage I | Beta-2 Microglobulin (B2M) <3.5 mg/L AND Albumin ≥3.5 g/dL |
| Stage II | Neither Stage I nor Stage III |
| Stage III | Beta-2 Microglobulin (B2M) ≥5.5 mg/L |
R-ISS — Adding Cytogenetics & LDH
| R-ISS Stage | Definition |
|---|---|
| R-ISS I | ISS Stage I AND Standard-risk cytogenetics AND Normal LDH |
| R-ISS II | All other cases (the "middle" group) |
| R-ISS III | ISS Stage III AND EITHER High-risk CA (del17p, t4;14, t14;16) OR High LDH |
R2-ISS (2022) — The Preferred System in 2026
The R2-ISS uses a weighted scoring system (0–5 points) and specifically incorporates 1q21 gain/amplification, which R-ISS omitted.
R2-ISS Scoring Criteria
- ISS Stage III (B2M >5.5, Alb <3.5): 1.5 points
- ISS Stage II: 1 point
- ISS Stage I (B2M <3.5, Alb ≥3.5): 0 points
- High-Risk Cytogenetics (del17p, t(4;14), t(14;16)): 1 point
- 1q Gain/Amplification: 0.5 points
- Elevated LDH (above ULN): 0.5 points
R2-ISS Stage Cutoffs
- Low Risk (R2-ISS I): 0 points
- Intermediate-Low (R2-ISS II): 0.5–1 point
- Intermediate-High (R2-ISS III): 1.5–2.5 points
- High Risk (R2-ISS IV): 3–5 points
NCCN v1.2026 / ESMO 2025 — Prognostic & Management Implications
Viva Questions & Clinical Pearls
Q: A patient has IgA myeloma but the SPEP M-spike is small. How do you quantify disease?
A: IgA myeloma can migrate in the beta-region on SPEP, leading to underestimation of the M-spike because IgA co-migrates with Transferrin and C3. Rely on quantitative IgA nephelometry rather than the SPEP M-spike measurement alone. Also cross-reference with sFLC for light chain burden. At response assessment, remember beta-migrating spikes are the reason IgA is traditionally harder to track — the immunofixation pattern is the definitive qualitative guide.
Q: How do you distinguish IgM Myeloma from Waldenström Macroglobulinemia?
A: Perform bone marrow biopsy with flow cytometry and FISH. If cells are CD20+ and MYD88 L265P-mutated → diagnose WM; initiate BTK inhibitor (Zanubrutinib preferred per ASPEN trial). If marrow shows CD138+, CD20−, CD19− clonal plasma cells carrying t(11;14) → diagnose IgM-MM. This distinction is critical: IgM-MM is an aggressive plasma cell dyscrasia requiring Dara-VRd + ASCT, and these patients are uniquely candidates for Venetoclax therapy due to near-universal t(11;14) status.
Q: A patient meets the 20-2-20 criteria for High-Risk SMM. Do you start D-VRd induction immediately?
A: No — standard of care outside a clinical trial is observation or Lenalidomide monotherapy, not D-VRd. The ECOG E3A06 trial showed Lenalidomide significantly delayed progression to active MM, but no trial has yet shown that early intensive treatment improves Overall Survival. Discuss risks and benefits with the patient; offer Lenalidomide or enrolment in a clinical trial (e.g., DETERMINATION or ASCENT). Also order Whole-Body MRI — if >1 focal lesion ≥5mm is found, the diagnosis changes to Active MM (SLiM criterion "M") and you must start induction immediately.
Q: Why is the R2-ISS preferred over R-ISS in 2026, and how does it change maintenance decisions?
A: The R2-ISS (published JCO 2022) adds weighted points for 1q21 gain/amplification (0.5 points) — a key prognostic feature omitted from the original R-ISS. It classifies patients into four risk groups (Low, Intermediate-Low, Intermediate-High, High) using a 0–5 point scoring system combining ISS stage, high-risk FISH (del17p, t4;14, t14;16), 1q gain, and LDH. Critically, risk category drives maintenance: Standard-risk patients receive single-agent Lenalidomide; High-risk patients (R2-ISS IV, or Double/Triple-hit) receive doublet maintenance — typically Bortezomib + Lenalidomide or Daratumumab + Lenalidomide — often indefinitely. MRD negativity at 10⁻⁶ can overcome the poor prognosis of a high R2-ISS score and is now the most important dynamic prognostic marker.
Clinical Decision Support
Pair these clinical notes with our validated calculators for a complete decision workflow.
ECOG Performance Status
Functional status assessment
G8 Geriatric Screening
Geriatric fitness for chemotherapy
Charlson Comorbidity Index
Comorbidity-adjusted prognosis
Khorana VTE Risk Score
VTE risk in cancer patients
CARG Chemo Toxicity
Geriatric chemotherapy toxicity
MGPS Prognostic Score
Modified Glasgow Prognostic Score
Clinical reference only. These notes are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines where applicable.